Dr. Wallace is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2900 North Loop W
Ste 1300
Houston, TX 77092Phone+1 773-292-4800Fax+1 312-564-4059- Is this information wrong?
Education & Training
- Methodist Hospital (Houston) San JacintoResidency, Family Medicine, 1994 - 1997
- University of Texas Medical Branch School of MedicineClass of 1994
Certifications & Licensure
- MI State Medical License 2015 - 2025
- OK State Medical License 2019 - 2025
- KS State Medical License 2015 - 2024
- TX State Medical License 1996 - 2024
- LA State Medical License 2015 - 2020
- OH State Medical License 2015 - 2019
- American Board of Family Medicine Family Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification athenaClinicals EHR, athenahealth, Inc, 2012-2013
Publications & Presentations
PubMed
- Phase II trial of continuous dosing of sunitinib in advanced, FDG-PET avid, medullary thyroid carcinoma (MTC) and well-differentiated thyroid cancer (WDTC).Carr L, Goulart B, Martins R, Keith E, Kell E, Wallace S, Capell P, Mankoff D> ;J. Clin. Oncol.. 2009-05-20
- Minimally increased risk of cerebrovascular occlusive disease or intracerebral hemorrhage in patients on bevacizumab treatment and association with intracerebral malig...Oh Y, Wallace S, Taylor S, Herbst RS, Lippman SM, Karp DD, Stewart DJ> ;J. Clin. Oncol.. 2008-05-20
- Phase II study of sunitinib in iodine refractory, well-differentiated thyroid cancer (WDTC) and metastatic medullary thyroid carcinoma (MTC).Goulart B, Carr L, Martins RG, Eaton K, Kell E, Wallace S, Capell P, Mankoff D> ;J. Clin. Oncol.. 2008-05-20
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: